MOONLAKE IMMUNO (MLTX)
(Real Time Quote from BATS)
$44.99 USD
+1.93 (4.48%)
Updated Aug 8, 2024 03:50 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
MoonLake Immunotherapeutics [MLTX]
Reports for Purchase
Showing records 61 - 80 ( 95 total )
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Revisiting Our Valuation Ahead of Multiple Ph2 Readouts; PT to $86
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Opportunity to Drive Additional Value with Upcoming Ph2 PsA HS Readouts in Q4
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Psoriatic Arthritis Data in November; More HS Data in October; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Sonelokimab Phase 2 Home Run in Hidradenitis Suppurativa; Raising PT to $75
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Company: MoonLake Immunotherapeutics
Industry: Unclassified
SLK in A League of Its Own in HS with Impressive Ph2 Data
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: MoonLake Immunotherapeutics
Industry: Unclassified
MIRAculous Ph2 SLK Data Usher in a New ERA in HS - Highlights from RD Call
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Company: MoonLake Immunotherapeutics
Industry: Unclassified
IL-17 Acquisition Deal Bodes Well for MoonLake, in Our View; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Gauging Expectations for the Ph2 SLK/HS Readout with Investor Survey
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Sonelokimab Phase 2 HS Data Imminent; 1Q23 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Momentum Continues to Build Ahead of Ph2 Readout
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Competitor IPO Shows Avid Interest in IL-17-Targeted Agents; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Autoinjector Collaboration to Optimize Sonelokimab Delivery; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Capital Markets Day Underscores SLK''s Competitive Advantage; Adding to BIL
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Capital Markets Day Highlights SLK Differentiation; Raising PT to $30
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R